BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37415407)

  • 21. VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations.
    Caliò A; Brunelli M; Segala D; Pedron S; Doglioni C; Argani P; Martignoni G
    Mod Pathol; 2019 Feb; 32(2):258-268. PubMed ID: 30206412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1.
    Zhang C; Duan Y; Xia M; Dong Y; Chen Y; Zheng L; Chai S; Zhang Q; Wei Z; Liu N; Wang J; Sun C; Tang Z; Cheng X; Wu J; Wang G; Zheng F; Laurence A; Li B; Yang XP
    Clin Cancer Res; 2019 Nov; 25(22):6827-6838. PubMed ID: 31383732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of TFEB-amplified renal cell carcinoma with focus on clinical and pathobiological aspects.
    Kuroda N; Sugawara E; Ohe C; Kojima F; Ohashi R; Mikami S; Nagashima Y; Peckova K; Michal M; Hes O
    Pol J Pathol; 2021; 72(3):197-199. PubMed ID: 35048631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Translocation carcinomas of the kidney.
    Argani P
    Genes Chromosomes Cancer; 2022 May; 61(5):219-227. PubMed ID: 34704642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.
    Gupta S; Johnson SH; Vasmatzis G; Porath B; Rustin JG; Rao P; Costello BA; Leibovich BC; Thompson RH; Cheville JC; Sukov WR
    Mod Pathol; 2017 Jul; 30(7):998-1012. PubMed ID: 28338654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive study of three novel cases of TFEB-amplified renal cell carcinoma and review of the literature: Evidence for a specific entity with poor outcome.
    Mendel L; Ambrosetti D; Bodokh Y; Ngo-Mai M; Durand M; Simbsler-Michel C; Delhorbe M; Amiel J; Pedeutour F
    Genes Chromosomes Cancer; 2018 Mar; 57(3):99-113. PubMed ID: 29127730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms.
    Caliò A; Marletta S; Brunelli M; Pedron S; Portillo SC; Segala D; Bariani E; Gobbo S; Netto G; Martignoni G
    Virchows Arch; 2022 Dec; 481(6):877-891. PubMed ID: 35980471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics and outcome of pediatric renal cell carcinoma patients registered in the International Society of Pediatric Oncology (SIOP) 93-01, 2001 and UK-IMPORT database: A report of the SIOP-Renal Tumor Study Group.
    van der Beek JN; Hol JA; Coulomb-l'Hermine A; Graf N; van Tinteren H; Pritchard-Jones K; Houwing ME; de Krijger RR; Vujanic GM; Dzhuma K; Schenk JP; Littooij AS; Ramírez-Villar GL; Murphy D; Ray S; Al-Saadi R; Gessler M; Godzinski J; Ruebe C; Collini P; Verschuur AC; Frisk T; Vokuhl C; Hulsbergen-van de Kaa CA; de Camargo B; Sandstedt B; Selle B; Tytgat GAM; van den Heuvel-Eibrink MM
    Int J Cancer; 2021 Jun; 148(11):2724-2735. PubMed ID: 33460450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lessons from 801 clinical TFE3/TFEB fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrations.
    Wang XM; Shao L; Xiao H; Myers JL; Pantanowitz L; Skala SL; Udager AM; Vaishampayan U; Mannan R; Dhanasekaran SM; Chinnaiyan AM; Betz BL; Brown N; Mehra R
    Am J Clin Pathol; 2023 Dec; 160(6):549-554. PubMed ID: 37499055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The New WHO Category of "Molecularly Defined Renal Carcinomas": Clinical and Diagnostic Features and Management Implications.
    Kanakaraj J; Chang J; Hampton LJ; Smith SC
    Urol Oncol; 2024 Jul; 42(7):211-219. PubMed ID: 38519377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
    Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification.
    Brunelli M; Erdini F; Cima L; Eccher A; Fioravanzo A; Gobbo S; Segala D; Ghimenton C; Mazzoleni G; Munari E; Carella R; Martignoni G
    Appl Immunohistochem Mol Morphol; 2018; 26(5):316-323. PubMed ID: 27556823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing.
    Cajaiba MM; Dyer LM; Geller JI; Jennings LJ; George D; Kirschmann D; Rohan SM; Cost NG; Khanna G; Mullen EA; Dome JS; Fernandez CV; Perlman EJ
    Cancer; 2018 Aug; 124(16):3381-3389. PubMed ID: 29905933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiT Family Translocation-Associated Renal Cell Carcinoma: A Contemporary Update With Emphasis on Morphologic, Immunophenotypic, and Molecular Mimics.
    Magers MJ; Udager AM; Mehra R
    Arch Pathol Lab Med; 2015 Oct; 139(10):1224-33. PubMed ID: 26414466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization.
    Rao Q; Liu B; Cheng L; Zhu Y; Shi QL; Wu B; Jiang SJ; Wang Y; Wang X; Yu B; Zhang RS; Ma HH; Lu ZF; Tu P; Wang JD; Zhou XJ
    Am J Surg Pathol; 2012 Sep; 36(9):1327-38. PubMed ID: 22895266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal cell carcinomas with t(6;11)(p21;q12) presenting with tubulocystic renal cell carcinoma-like features.
    Rao Q; Zhang XM; Tu P; Xia QY; Shen Q; Zhou XJ; Shi QL
    Int J Clin Exp Pathol; 2013; 6(7):1452-7. PubMed ID: 23826432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re-evaluation of histological type by immunohistochemical and genetic study of transcription factors (TFE3 and TFEB) of VHL gene mutation-negative clear cell renal cell carcinoma and other special types of renal tumor.
    Kuroda N; Kawada C; Tamura K; Hiroi M; Hes O; Michal M; Wada Y; Inoue K; Ohara M; Mizuno K; Shuin T; Lee GH
    Med Mol Morphol; 2011 Mar; 44(1):46-51. PubMed ID: 21424937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translocation renal cell carcinomas in adults: a single-institution experience.
    Zhong M; De Angelo P; Osborne L; Paniz-Mondolfi AE; Geller M; Yang Y; Linehan WM; Merino MJ; Cordon-Cardo C; Cai D
    Am J Surg Pathol; 2012 May; 36(5):654-62. PubMed ID: 22446944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
    Martignoni G; Pea M; Gobbo S; Brunelli M; Bonetti F; Segala D; Pan CC; Netto G; Doglioni C; Hes O; Argani P; Chilosi M
    Mod Pathol; 2009 Aug; 22(8):1016-22. PubMed ID: 19396149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical experience and literature review.
    He J; Chen X; Gan W; Zhu B; Fan X; Guo H; Jia R
    Future Oncol; 2015; 11(24):3243-52. PubMed ID: 26169997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.